Donepezil vs Rivastigmine

How they're similar

Donepezil and rivastigmine sit in the same drug class and work through the same general mechanism. They inhibit cholinesterase enzymes, which slows the breakdown of acetylcholine, a chemical messenger that supports memory and attention and that's lost early in Alzheimer's.

• Both are symptomatic treatments. Neither modifies the disease.
• Both offer modest effect sizes in trials. On cognitive rating scales, the average improvement is around 3 to 4 points, and much of what looks like benefit is really a period of stability rather than a return of lost function.
• Both share a core set of cholinergic side effects: nausea, vomiting, diarrhea, weight loss, vivid dreams, muscle cramps, slow heart rate, and rare fainting.
• Both need to be titrated carefully to reduce the GI side effects that come with cholinergic stimulation.
• Both are widely available as generics.
• Both should be tapered off rather than stopped abruptly, since sudden discontinuation can lead to a sharper drop in function.

At day-to-day level, the experience of starting either drug looks similar. Side effects usually arrive before any benefit, they show up in the gut first, and they either fade with time or lead to a dose adjustment. Choosing between these two often comes down to formulation and tolerability rather than efficacy.

How they differ

The differences are mostly in enzyme targets, formulation, and approved uses.

Rivastigmine inhibits butyrylcholinesterase as well as acetylcholinesterase. Butyrylcholinesterase seems to become more important as Alzheimer's progresses, which is one theoretical reason rivastigmine has been studied more in later disease. Whether that translates into meaningful clinical differences for individual patients isn't fully settled.

Rivastigmine is FDA-approved for Parkinson's disease dementia, which donepezil is not. Cognitive impairment in Parkinson's is common as the disease advances, and rivastigmine has real evidence in this population. Donepezil is sometimes used off-label in Parkinson's dementia, but rivastigmine has the formal approval and the better studied path.

The formulation piece is where the real practical difference lives. Donepezil is oral only, usually taken once daily at bedtime. Rivastigmine oral is dosed twice daily and needs slow titration to minimize GI side effects. Rivastigmine transdermal patch delivers the drug through the skin over 24 hours and is applied once a day to a rotating spot on the back, chest, or upper arm.

The IDEAL trial and follow-on studies showed that the higher-dose rivastigmine patch (13.3 mg/24h) delivers efficacy comparable to the highest tolerable oral dose, with dramatically less nausea, vomiting, and weight loss. That better tolerability is the main reason rivastigmine is used at all these days. Very few new prescriptions are for oral rivastigmine capsules, since the patch does the same clinical work with less GI trouble.

Side effect tendencies

Both drugs share the same category of side effects because they both raise acetylcholine everywhere in the body.

Donepezil's most common issues are nausea, diarrhea, decreased appetite, weight loss, and vivid dreams. Slower heart rate is a real concern, especially in someone on a beta-blocker or with a known conduction problem, and rarely it can cause fainting. Muscle cramps and increased urination round out the common list. Most side effects arrive early and either fade or lead to a dose adjustment.

Oral rivastigmine has a rougher GI profile than donepezil. Nausea, vomiting, and weight loss are common enough that many people can't reach a full therapeutic dose. That's the main reason the oral formulation has largely been supplanted by the patch.

Rivastigmine patch has a much better GI profile. The drug is absorbed slowly through the skin, which avoids the peaks that seem to drive the worst of the nausea and vomiting. Instead, the main issue with the patch is skin irritation at the application site, which is why rotating sites is important. Some redness, itching, or rash can happen, and severe reactions rarely require stopping the patch.

Both drugs share the cholinergic risks of bradycardia and syncope. In someone with symptomatic bradycardia, sick sinus syndrome, or a history of unexplained fainting, either drug should be used with caution or avoided.

What tips the choice

For a first cholinesterase inhibitor in Alzheimer's disease, donepezil is usually the practical starting point. It's once daily, well tolerated for most people, and has decades of prescribing experience behind it.

If donepezil isn't tolerated, the rivastigmine patch is often the next step. Some people who can't handle donepezil's oral GI effects do fine on the transdermal patch, because absorption through the skin avoids the peaks that drive the worst nausea.

If the underlying diagnosis is Parkinson's disease dementia, rivastigmine has the formal approval and the better evidence base. That's a clear situation where rivastigmine is the drug of choice, usually in patch form.

For someone with swallowing difficulty, the patch is a real advantage. Same for someone whose caregiver has trouble with a daily pill routine but can apply and rotate a patch reliably.

For someone with severe Alzheimer's, donepezil has both the 10 mg and 23 mg options, and rivastigmine has the 13.3 mg/24h patch. Either is reasonable, and choice often comes down to prior tolerability and what the family finds workable.

Cost is generally not the deciding factor. Both drugs are available as generics. The rivastigmine patch is sometimes a little pricier than oral options depending on the plan, but for most people it's affordable.

Skin issues can rule out the patch. In someone with widespread skin disease, active dermatitis, or a history of poor patch tolerance, oral options are safer.

Common questions

Is one of these more effective than the other? No, not in a way that changes practice. Head-to-head trials show broadly similar effects on cognition and daily function. What's different is the side effect profile and the formulation options. Rivastigmine is somewhat unique in also inhibiting butyrylcholinesterase, but whether that matters clinically is unclear.

Why is the rivastigmine patch preferred over the capsule? The patch delivers the drug slowly through the skin, which avoids the peaks that seem to drive the worst nausea and vomiting. The IDEAL trial showed that the higher-strength patch reaches similar efficacy to the highest tolerable oral dose, with much better GI tolerability. In practice, almost no one starts on oral rivastigmine anymore.

Can I switch from donepezil to rivastigmine? Yes, and it's a reasonable step if donepezil isn't tolerated. Some clinicians do a direct switch after stopping donepezil for a few days. Others cross-taper. The plan should be set with the prescriber, since both drugs have cholinergic effects and stacking them isn't safe.

Does rivastigmine work for Parkinson's disease? It's approved for Parkinson's disease dementia, meaning the cognitive impairment that shows up as Parkinson's progresses. It doesn't treat the movement symptoms of Parkinson's, which are treated with different medications like levodopa. Donepezil isn't formally approved for Parkinson's dementia, though it's sometimes used off-label.

How long does the benefit last? Modest cognitive support tends to last for a period of months to a few years, and then the disease progresses beyond what the drug can offset. Some families choose to continue the medication through later stages. Others stop it when swallowing becomes unsafe, when side effects outweigh benefit, or when goals of care shift toward comfort.

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes. This is not medical advice.

1. U.S. Food and Drug Administration. Donepezil prescribing information.
2. U.S. Food and Drug Administration. Rivastigmine prescribing information.
3. MedlinePlus, U.S. National Library of Medicine.
4. National Institute on Aging. Alzheimer's disease and Parkinson's dementia treatment resources.